US Frontotemporal Dementia Market to Witness Healthy Growth Rate until 2025

Increasing funding by government for healthcare sector and growing number of dementia cases to drive United States frontotemporal dementia market

According to TechSci Research report, “United States Frontotemporal Dementia Market By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Region, Forecast & Opportunities, 2025”, the market is expected to undergo significant growth during the forecast period owing to increasing life expectancy rate in the country and growing geriatric population, which is more prone to neurodegenerative diseases such as frontotemporal dementia. Additionally, increasing funding by United States government for healthcare sector, to encourage research & development activities, is also a major growth driver for this market. Furthermore, various non-profit organizations are also raising funds for drug developments, which is expected to drive the growth of United States frontotemporal dementia market in the coming years.

Moreover, growing awareness among citizens towards health and about frontotemporal dementia, is acting as another growth factor for this market.  Additionally, availability of advanced healthcare treatment centers such as mental treatment centers and home care administrations is further boosting the growth of frontotemporal dementia market in the country.

However, United States frontotemporal dementia market is also facing some challenges. The country is witnessing lack of approved drugs for frontotemporal treatment and high failure rate of clinical trials which is a major setback for the market. Furthermore, high chances of being confused with Alzheimer’s disease is also hampering the growth of frontotemporal dementia market.

Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “United States Frontotemporal Dementia Market”

https://www.techsciresearch.com/report/united-states-frontotemporal-dementia-market/4863.html

The United States frontotemporal dementia market is segmented based on drug class type, disease type, distribution channel, end user and region. Based on disease type, the market is segmented into Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA) and others. Currently, the country is witnessing high prevalence of behavior variant frontotemporal dementia on account of which, the segment is expected to undergo high growth rate during the forecast period. Some of the common symptoms of behavior variant frontotemporal dementia include behavioral changes, apathy and changes in stereotypic behavior. Based on drug class type, the United States United States frontotemporal dementia market is categorized into antidepressants and antipsychotics. Here, the demand for antidepressant drugs is comparatively high in the country as they are being extensively used to minimize the behavioral problems associated with frontotemporal dementia. The segment is therefore expected to dominate the market until 2025 as more physicians are also recommending anti-depressants for the treatment of frontotemporal dementia.

Major players operating in the United States frontotemporal dementia market include Pfizer Inc., Novartis Corporation, Hoffmann-La Roche, Inc., AstraZeneca Pharmaceuticals LP, Sanofi-Aventis US LLC, Merck & Co., Inc., Alector, Inc., GlaxoSmithKline LLC, Allergan USA, Inc., Eli Lilly and Company, Johnson & Johnson and Mylan Pharmaceuticals, Inc. The market is witnessing entry of new manufacturers on account of increasing competition. Additionally, leading companies are investing on R&D activities for new drug developments.

Download Sample Report  @ https://www.techsciresearch.com/sample-report.aspx?cid=4863

Customers can also request for 10% free customization on this report.

“Increasing cases of frontotemporal dementia in United States is providing new opportunities for drug manufacturers to expand their market in the country. Additionally, health policies and reimbursements provided by the US government is giving a major boost to the market growth. Also, use of latest technologies by manufacturers for clinical trials is expected to open new horizons for the frontotemporal dementia market in the country,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Frontotemporal Dementia Market By Drug Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Region, Forecast & Opportunities, 2025”has evaluated the future growth potential of United States frontotemporal dementia market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in United States frontotemporal dementia market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]